CU-CPT-9a is a selective agonist of the GPR35 receptor, making it a valuable tool in pharmacological research focused on inflammatory and metabolic diseases. It is commonly used in studies exploring the role of GPR35 in immune regulation, particularly in models of colitis and other gastrointestinal inflammatory conditions. The compound has shown potential in modulating cytokine production and immune cell activity, suggesting possible applications in developing treatments for autoimmune disorders. Additionally, CU-CPT-9a is employed in diabetes-related research due to GPR35’s involvement in insulin secretion and glucose homeostasis. Its high selectivity allows for precise activation of GPR35 pathways, facilitating clearer interpretation of receptor function in cellular and animal models.